Operator fluency on fresh ground

Supernus Pharmaceuticals, Inc. (SUPN) — this company's answers

The model's full reasoning — Q3 2016 call → NOWe need to answer YES or NO based on the criteria. The question asks: "On this call, when analysts probe a RECENTLY EMERGED positive element of the business — something whose meaningful contribution began only within roughly the last few quarters — does management respond with UNHESITATING, GRANULAR OPERATIONAL COMMAND: answering follow-up questions about that new element with specific, present-tense working detail ... while conveying that the element's contribution to the reported results is still early?" We need to identify if there is such an element. The call discusses several things: product sales growth, pipeline (SPN-810, SPN-812), IP litigation, business development, and a restatement. The "recently emerged positive element" could be SPN-812's positive Phase 2b results, which were announced in October 2016, just before this call (November 14, 2016). That is a recent positive development. Analysts probe it? Let's see the Q&A. Analysts ask about Trokendi XR litigation, business development, SPN-810 enrollment, gross to nets, etc. There is a question about SPN-812: "On 812, you had shown us that there was clearly a dose response, and that there was a very high tolerability and low adverse event profile. Is there any reason to try a higher dose, given that tolerability, and push that efficacy fully into the range of the stimulants?" That is a follow-up on SPN-812. Management responds: "That is certainly a possibility we are looking at now very, very carefully, absolutely. We are looking at an end of Phase 2 meeting, we’re trying to set that up as soon as we can with the FDA, and clearly that would be part of the topics that we will be discussing with the FDA, including the design of the Phase 3, the doses and so forth. Clearly, that is a clear advantage that we see at this point, given all the data that we’ve generated so far. This drug has a great potential even if we push it higher, that it will give us a very nice efficacy. Having said that, just as a reminder for folks, the efficacy we saw on the Phase 2B is truly remarkable for a non-stimulant, with the effect sizes that are actually close to some of the stimulants on the market today, and again, at the doses we tested.

← Back to the full SUPN analysis